Neuroblastoma
- Cells1
Trial sponsors
Company1 trialPhase 2128 people
Company1 trialPhase 1/238 people
Company1 trialPhase 1143 people
Company1 trialPhase 14 people
13 trialsPhase 34,283 people
Children's Cancer and Leukaemia Group
7 trialsPhase 3143 people
Children's Hospital Medical Center, Cincinnati
3 trialsPhase 3574 people
German Society for Pediatric Oncology and Hematology GPOH gGmbH
2 trialsPhase 3642 people
Latest
6 in 12 monthsNeurotoxicology
T-2 toxin disrupts Alzheimer's-relevant App/Tau homeostasis via circadian-p53-senescence crosstalk: Evidence from human neuroblastoma cells
Experiments in human cellsProteostasis
AAIC 2025 Abstract
Brain‐Derived Tau Oligomers in Circulating Extracellular Vesicles as Predictive Biomarkers for Alzheimer's Disease Conversion
Cohort study in peopleTau
AAIC 2025 Abstract
Repurposing of aging‐preventive pharmaceuticals to delay Alzheimer's disease progression.
Cohort study of 672 peopleAlzheimer's disease
AAIC 2025 Abstract
Spatiotemporal differential regulation of extrasynaptic GluN2B receptor subunits and PSA‐NCAM in brain aging and Alzheimer's disease
Experiments in 4 miceMechanisms
Biomedicines
Loss of AT8 Nuclear Tau as a Marker of Neuronal Ageing and Alzheimer's Disease Progression
Cross-sectional study in peopleMechanisms
Cellular and Molecular Life Sciences
Comparing loss of individual fragile X proteins suggests strong links to cellular senescence and aging
Experiments in human cellsCellular senescence
GSA 2024 Abstract
N6-METHYLDEOXYADENOSINE (N6MEDA) IS ASSOCIATED WITH AGING
Cross-sectional study in peopleMechanisms